Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06139991 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT06139991 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 66 participants.
The verdict
NCT06139991, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study will investigate the Pharmacokinetic (PK) and safety of Budesonide and albuterol (BDA) metered dose inhaler (MDI) HFO and BDA MDI HFA in healthy male and female participants.
Interventions
- DRUG Treatment A (BDA MDI HFO)
- DRUG Treatment B (BDA MDI HFA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-11-16 |
| Est. Completion | 2024-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06139991
The ClinicalTrials.gov registry entry for NCT06139991 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment A (BDA MDI HFO) is the first listed.
NCT06139991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06139991 about?
NCT06139991 is a clinical study titled "Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.". This study will investigate the Pharmacokinetic (PK) and safety of Budesonide and albuterol (BDA) metered dose inhaler (MDI) HFO and BDA MDI HFA in healthy male and female participants.
What is the current status of trial NCT06139991?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2023-11-16. Estimated completion is 2024-05-04.
What interventions are being tested in trial NCT06139991?
The interventions under investigation include: Treatment A (BDA MDI HFO) (DRUG), Treatment B (BDA MDI HFA) (DRUG).
Who is sponsoring clinical trial NCT06139991?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.